Table 5. Post-treatments after tumor progression in two groups.
| Treatments | TACE-sorafenib group (n=115) | TACE-apatinib group (n=86) | P |
|---|---|---|---|
| Ablative therapy | 14 (12.2) | 21 (24.4) | 0.024 |
| Palliative surgery | 5 (4.3) | 2 (2.3) | 0.700 |
| Radioactive seed implanting (iodine-125) | 15 (13.0) | 18 (20.9) | 0.135 |
| Radiotherapy | 3 (2.6) | 1 (1.2) | 0.829 |
| New target agents | 5 (4.3) | 8 (9.3) | 0.158 |
| Sorafenib | 0 (0.0) | 7 (8.1) | 0.006 |
| Regorafenib | 5 (4.3) | 1 (1.2) | 0.371 |
| Intra-arterial infusion | 5 (4.3) | 6 (7.0) | 0.619 |
| Immunotherapy | 4 (3.5) | 4 (4.7) | 0.955 |
Data are shown as numbers of events with percentages in parentheses. TACE, transarterial chemoembolization.